File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia

TitleAlemtuzumab induced complete remission of therapy-resistant pure red cell aplasia
Authors
Issue Date2005
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukres
Citation
Leukemia Research, 2005, v. 29 n. 10, p. 1213-1215 How to Cite?
AbstractTwo patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases. © 2005 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/77624
ISSN
2015 Impact Factor: 2.606
2015 SCImago Journal Rankings: 1.043
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLam, CCKen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorPang, AWKen_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:33:56Z-
dc.date.available2010-09-06T07:33:56Z-
dc.date.issued2005en_HK
dc.identifier.citationLeukemia Research, 2005, v. 29 n. 10, p. 1213-1215en_HK
dc.identifier.issn0145-2126en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77624-
dc.description.abstractTwo patients with pure red cell aplasia (PRCA) refractory to anti-thymocyte globulin, prednisolone, cyclophosphamide, fludarabine, mitoxantrone, dexamethasone and cyclosporine, were treated with alemtuzumab (anti-CD52 antibody). Case 1, a 35-year-old man with idiopathic PRCA, remitted completely with 130 mg of alemtuzumab. Case 2, a 42-year-old man with PRCA due to T-cell large granular lymphocyte (T-LGL) leukaemia, achieved complete remission of the PRCA with 490 mg of alemtuzumab, although the T-LGL leukaemia responded only transiently. There were no significant side effects, and normalization of erythropoiesis was durable. Alemtuzumab is active in PRCA that is idiopathic or secondary to T-cell lymphoproliferative diseases. © 2005 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/leukresen_HK
dc.relation.ispartofLeukemia Researchen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntibodies, Monoclonal - therapeutic useen_HK
dc.subject.meshAntibodies, Monoclonal, Humanizeden_HK
dc.subject.meshAntibodies, Neoplasm - therapeutic useen_HK
dc.subject.meshAntilymphocyte Serum - administration & dosageen_HK
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshCyclophosphamide - administration & dosageen_HK
dc.subject.meshCyclosporine - administration & dosageen_HK
dc.subject.meshDexamethasone - administration & dosageen_HK
dc.subject.meshDrug Resistance, Neoplasmen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLeukemia, T-Cell - complications - drug therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMitoxantrone - administration & dosageen_HK
dc.subject.meshPrednisolone - administration & dosageen_HK
dc.subject.meshRed-Cell Aplasia, Pure - complications - drug therapyen_HK
dc.subject.meshRemission Inductionen_HK
dc.subject.meshVidarabine - administration & dosage - analogs & derivativesen_HK
dc.titleAlemtuzumab induced complete remission of therapy-resistant pure red cell aplasiaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0145-2126&volume=29 Issue 10&spage=1213&epage=1215 &date=2005&atitle=Alemtuzumab+induced+complete+remission+of+therapy-resistant+pure+red+cell+aplasia+en_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.leukres.2005.02.018en_HK
dc.identifier.pmid16111536-
dc.identifier.scopuseid_2-s2.0-23844518658en_HK
dc.identifier.hkuros120284en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23844518658&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1213en_HK
dc.identifier.epage1215en_HK
dc.identifier.isiWOS:000231786800015-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLam, CCK=16947291300en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridPang, AWK=7007044165en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats